A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Current approaches to identifying drug-drug interactions (DDIs), which involve clinical evaluation of drugs and post-marketing surveillance, are unable to provide complete, accurate information, nor do they alert the public to potentially dangerous DDIs before the drugs reach the market. Predicting potential drug-drug interaction helps reduce unanticipated drug interactions and drug development costs and optimizes the drug design process. Many bioinformatics databases have begun to presentdoi:10.6084/m9.figshare.7325186 fatcat:mddmxn3gnngybmycbr7yi7tgsu